Medicine and Dentistry
Sickle-Cell Disease
100%
Child
89%
Pain
77%
Patient
43%
Pediatrics
35%
Ocular Albinism
30%
Combination Therapy
26%
Inpatient
24%
Therapeutic Procedure
24%
Methadone
20%
Life
20%
Acute Chest Syndrome
18%
Thromboelastography
18%
Acute Lymphoblastic Leukemia
18%
Hemophagocytic Syndrome
18%
Pediatrician
18%
Blood
18%
Heart Surgery
18%
Haemophilia
18%
Analgesia
16%
Diagnosis
16%
Philadelphia 1 Chromosome
16%
Interstitial Lung Disease
15%
Adult
15%
Thalidomide
13%
Clinician
13%
Age
12%
Janus Kinase
12%
Toxicity
11%
Transfusion
11%
Outpatient
10%
Opiate
10%
Brain Hemangioma
9%
Capillary Hemangioma
9%
Blood Product
9%
Growth Rate
9%
Fibroblast Growth Factor 2
9%
Hemangioma
9%
Neoplasm
9%
Vasculotropin
9%
Pulmonary Fibrosis
9%
Male
9%
Evaluation Study
9%
Sulfhemoglobinemia
9%
Emicizumab
9%
Concizumab
9%
Asthma
8%
Complication
8%
Cytotoxicity
8%
Adolescent
8%
Nursing and Health Professions
Sickle Cell Anemia
57%
Pain
55%
Patient
48%
Child
36%
Hospital Readmission
29%
Acute Chest Syndrome
18%
Blood Cell Count
18%
Emergency Ward
17%
Diagnosis
16%
Inpatient
14%
Clinician
13%
Caregiver
10%
Hematologic Disease
9%
Evaluation Study
9%
Asthma
8%
Pediatric Hospital
7%
Time
7%
Procedures
6%
Hospitalization
6%
Control
6%
Physician
5%
Opiate
5%
Analgesia
5%
Dose
5%
Discharge
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pain
34%
Sickle Cell Anemia
27%
Acute Chest Syndrome
18%
Hemophagocytic Syndrome
18%
Concizumab
18%
Sickle Cell Anemia
18%
Haemophilia
18%
Thalidomide
13%
Ocular Albinism
12%
Fibroblast Growth Factor 2
9%
Hemangioma
9%
Vasculotropin
9%
Neoplasm
9%
Brain Hemangioma
9%
Capillary Hemangioma
9%
Case Report
9%
Toxicity
9%
Complication
8%
Cytotoxicity
8%
Hemoglobinopathy
6%
Emicizumab
6%
Haemophilia A
6%
Concizumab
6%
